• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $XRTX

    XORTX Therapeutics Inc.

    Subscribe to $XRTX
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for XORTX Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    12/9/2021$11.00Buy
    Alliance Global Partners
    See more ratings

    XORTX Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • XORTX Provides Update on FDA Type B Meeting Request

      ● XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the "FDA") and clarified key steps for a new drug application ("NDA") for the Company's novel proprietary formulation of oxypurinol for the treatment of gout. The Type B meeting conducted by the FDA, included review of chemistry, manufacturing, ph

      4/30/25 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Announces Grant of European Patent

      CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease , is pleased to announce receipt of notification that the patent "Xanthine Oxidase Inhibitor Formulations" will be granted by the European Patent Office. The patent covers compositions and methods of formulating using XORTX's proprietary formulations of xanthine oxidase inhibitors ("XOI") for the treatment of health consequences of chronically high uric acid, gout, renal, cardiovascular and other diseases where abe

      4/28/25 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

      CALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces receipt of notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of US$1.

      4/17/25 7:45:00 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Announces Update for Discussion with the FDA

      ● Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, is pleased to provide an update regarding communications with the US Food and Drug Administration (the "FDA"). At the request of the FDA a type B meeting package will be provided by the Company during the next week, and accompanying FDA communications are expected by April 26, 2025. The Company has prepared a broad Type B meeting review at the r

      3/19/25 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Commences Gout Program NDA Discussions with the FDA

      ● Type C Meeting Requested to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, Feb. 24, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces that it has submitted a Type C meeting request with the US Food and Drug Administration (the "FDA") regarding the Company's XRx-026 program for the treatment of gout. Development of XORLO™ 1, the Company's proprietary drug formulation of oxypurinol, has advanced to the point where a Type C meeting and discussion with the FDA is warr

      2/24/25 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX to Present at Microcap Conference

      CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces attendance and presentation at the Microcap Conference hosted by DealFlow Events on January 28 through 30, 2025 in Atlantic City, NJ. Attendance at this conference continues outreach to the investment community and provides XORTX with an opportunity to update investors on our newly announced gout program. The presentation on January 29, 2025 will review the Company's plans to advance the XRx-026 program

      1/29/25 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Announces Change of Auditor

      CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces the Company has changed its auditor from Smythe LLP, Chartered Professional Accountants ("Former Auditor") to Davidson & Company LLP, Chartered Professional Accountants, ("Successor Auditor") effective January 16, 2025. XORTX's board of directors accepted the resignation of the Former Auditor, as of January 16, 2025 and appointed the Successor Auditor as the new auditor of the Company effective January 1

      1/17/25 5:00:00 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Adds Late Stage Gout Program to Pipeline

      CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the launch of a new late stage program to treat gout. The new drug development program - XRx-026 - will focus on the treatment of individuals who have gout and are intolerant to allopurinol. With the clinical development of XORLOTM 1 having advanced sufficiently, including completion of a pivotal program, XORTX is initiating discussions for the XRx-026 program with the US Food and Drug Administration ("FDA")

      1/6/25 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Strengthens Executive Team

      CALGARY, Alberta, Dec. 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Dr. Michael Bumby, a biotech/pharma industry veteran, as its Chief Financial Officer replacing James Fairbairn, the Company's current Chief Financial Officer. Dr. Bumby, DVM, MBA, is currently a director and audit committee chair of MediPharm Labs following their successful acquisition of VIVO Cannabis Inc. where Dr. Bumby was CFO for six years. Dr. Bumby brings over 20 years of finance and leadership experi

      12/19/24 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Announces Presentation at the Rare and Genetic Disease Summit

      CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a presentation by Dr. Allen Davidoff at the Rare and Genetic Kidney Disease Summit, in Boston, Massachusetts at 10:30 am ET, Thursday December 12, 2024. The presentation entitled "Autosomal Dominant Polycystic Kidney Disease - Genetic and Environmental Factors → Evidence for Aberrant Purine Metabolism as a Second Hit Determining Disease Progression." The presentation highlights XORTX recent pioneerin

      12/12/24 9:17:38 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    XORTX Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by XORTX Therapeutics Inc. (Amendment)

      SC 13G/A - XORTX Therapeutics Inc. (0001729214) (Subject)

      2/14/24 3:03:47 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by XORTX Therapeutics Inc.

      SC 13G - XORTX Therapeutics Inc. (0001729214) (Subject)

      2/14/23 1:48:46 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    XORTX Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on XORTX Therapeutics with a new price target

      Alliance Global Partners initiated coverage of XORTX Therapeutics with a rating of Buy and set a new price target of $11.00

      12/9/21 9:10:32 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    XORTX Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • XORTX Announces Results of Annual and Special Meeting of Shareholders

      CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the "Meeting") held Thursday, September 12, 2024. A total of 889,288 common shares of the Company were represented at the Meeting, representing approximately 31% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including electi

      9/13/24 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Welcomes New Member to the Board of Directors

      CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

      4/8/24 7:30:00 AM ET
      $GMDA
      $XRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • XORTX Announces New Clinical Advisory Board Member

      CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease ("ADPKD"), is pleased to announce that Dr. Ronald Perrone has joined the Company's Clinical Advisory Board. Dr. Allen Davidoff stated, "We are excited that Dr. Ron Perrone has agreed to join XORTX's Clinical Advisory Board. Dr. Perrone brings substantial medical and professional experience as a thought leader, combined with clinical experience treating patients with ADPKD and kidney disease. We are privileged

      3/27/24 5:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Welcomes New Member to the Board of Directors

      CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen, both effective December 31, 2023. Mr. Treanor is a seasoned pharmaceutical industry executive. He is the current Chief Operating Officer of Pathalys Pharma, Inc., a private company focused on the development of advanced therapeutics to improve the management of late stage chronic kidney disease. He previously served as Pre

      1/2/24 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Appoints Chief Financial Officer

      CALGARY, Alberta, Aug. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of James Fairbairn as Chief Financial Officer to replace Amar Keshri who left the Company's employ effective July 31, 2023. James Fairbairn was appointed Interim Chief Financial Officer on June 28, 2023. James Fairbairn was the Company's Chief Financial Officer from November 2018 through July 2021. He has more than 30 years of experience with publicly-traded companies. He is a Char

      8/4/23 5:00:00 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Announces Results of Annual and Special Meeting of Shareholders

      CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the "Meeting") held Wednesday, June 28, 2023. A total of 7,482,990 common shares of the Company were represented at the Meeting, representing approximately 41.6% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including electio

      6/29/23 8:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company's Upcoming Annual and Special Meeting of Shareholders

      The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26, 2023. XORTX's board of directors recommends shareholders vote FOR the election of all director nominees, FOR the appointment of auditors of the ensuing year, and FOR the resolution to approve the Company's stock option plan.Shareholders who have questions or need assistance with voting their shares can contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at [email protected]. CALGARY, Alberta, June 23, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pha

      6/23/23 8:51:20 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

      CALGARY, Alberta, Nov. 16, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Stacy Evans, M.D., MBA, as Chief Business Officer. The engagement of Dr. Evans initiates a business development outreach program associated with the Company's XRx-008 program, with the goal of identifying a global partner for Phase 3 development and commercialization. In addition, XORTX has appointed Russo Partners as the Company's Public Relations firm, with David Melamed, Ph.D.,

      11/16/22 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Welcomes New Member to the Board of Directors and Appoints Chair

      CALGARY, Alberta, June 06, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to welcome and appoint Mr. Anthony Giovinazzo to the Board of Directors and as Chair of the Board.  Dr. Allen Davidoff, CEO of XORTX stated, "I am pleased to welcome Anthony to the board of directors and as Chair of the Board. Mr. Giovinazzo's experience speaks for itself with decades of industry experience, including extensive patent portfolio building, pharmaceutical industry partnering, technology commercia

      6/6/22 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Announces Appointment of Chief Technology Officer

      CALGARY, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dr. David MacDonald as Chief Technology Officer (CTO). Dr. MacDonald has an over 30-year record of achievement in drug development and leadership in pharma and biotech, achieving critical, value-inflection milestones for those companies.  Dr. Allen Davidoff, CEO of XORTX stated, "We are delighted to welcome Dr. MacDonald to the management team and into a leadership role with the Company.

      1/20/22 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    XORTX Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • XORTX Announces Date for Rescheduled Special Meeting of Shareholders

      CALGARY, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its earlier press release, the special meeting of shareholders has been rescheduled to 10:00 a.m. (Calgary time) on Friday, October 27, 2023 (the "Meeting"). At the Meeting shareholders will consider a consolidation of the Company's issued and outstanding shares in order for the Company to regain compliance with the continued listing requirements for the NASDAQ Capital Market. About XORTX Therap

      10/25/23 5:00:00 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Therapeutics Announces Annual and Special Meeting of Shareholders

      CALGARY, Alberta, Nov. 23, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (TSXV:XRTX, NASDAQ:XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces that it will hold its annual and special meeting of shareholders at 11:00 a.m. (Calgary time) on Monday, December 20, 2021 (the "Meeting"). Materials for the Meeting have been mailed to shareholders and are available on the Company's SEDAR profile and the Company's website. The meeting has been called for shareholders to consider annual matters including the election of directors, re-appointment of Smythe LLP Chartered Accountants as au

      11/23/21 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    XORTX Therapeutics Inc. SEC Filings

    See more
    • SEC Form NT 20-F filed by XORTX Therapeutics Inc.

      NT 20-F - XORTX Therapeutics Inc. (0001729214) (Filer)

      5/1/25 7:00:29 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by XORTX Therapeutics Inc.

      6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

      4/30/25 7:00:09 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by XORTX Therapeutics Inc.

      6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

      4/28/25 7:00:07 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by XORTX Therapeutics Inc.

      6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

      4/17/25 7:49:35 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by XORTX Therapeutics Inc.

      6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

      4/1/25 3:38:15 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by XORTX Therapeutics Inc.

      6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

      3/26/25 11:01:26 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by XORTX Therapeutics Inc.

      6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

      3/19/25 2:54:59 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by XORTX Therapeutics Inc.

      6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

      2/24/25 8:18:25 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by XORTX Therapeutics Inc.

      SCHEDULE 13G - XORTX Therapeutics Inc. (0001729214) (Subject)

      2/14/25 5:04:07 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by XORTX Therapeutics Inc.

      6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

      1/29/25 7:03:57 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care